Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Yutaka Akimoto, Kazuhiro Nouso, Hironari Katou, Koji Miyahara, Chihiro Dohi, Yuki Morimoto, Hideaki Kunugasa, Takeshi Tomoda, Naoki Yamamoto, Koichiro Tsutsumi, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada, Maho Amano, Shin Ichiro Nishimura, Kazuhide Yamamoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95% confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95% CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.

Original languageEnglish
Pages (from-to)432-438
Number of pages7
JournalPancreatology
Volume15
Issue number4
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Pancreatic Neoplasms
Polysaccharides
Serum
Neoplasms
Odds Ratio
Confidence Intervals
Hematologic Tests
ROC Curve
Cysts
Multivariate Analysis

Keywords

  • Biological markers
  • Fucosylation
  • Glycomics
  • Intraductal papillary mucinous neoplasm
  • Malignancy
  • Pancreas

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology

Cite this

Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas. / Akimoto, Yutaka; Nouso, Kazuhiro; Katou, Hironari; Miyahara, Koji; Dohi, Chihiro; Morimoto, Yuki; Kunugasa, Hideaki; Tomoda, Takeshi; Yamamoto, Naoki; Tsutsumi, Koichiro; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Okada, Hiroyuki; Amano, Maho; Nishimura, Shin Ichiro; Yamamoto, Kazuhide.

In: Pancreatology, Vol. 15, No. 4, 01.07.2015, p. 432-438.

Research output: Contribution to journalArticle

Akimoto, Y, Nouso, K, Katou, H, Miyahara, K, Dohi, C, Morimoto, Y, Kunugasa, H, Tomoda, T, Yamamoto, N, Tsutsumi, K, Kuwaki, K, Ohnishi, H, Ikeda, F, Nakamura, S, Shiraha, H, Takaki, A, Okada, H, Amano, M, Nishimura, SI & Yamamoto, K 2015, 'Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas', Pancreatology, vol. 15, no. 4, pp. 432-438. https://doi.org/10.1016/j.pan.2015.05.470
Akimoto, Yutaka ; Nouso, Kazuhiro ; Katou, Hironari ; Miyahara, Koji ; Dohi, Chihiro ; Morimoto, Yuki ; Kunugasa, Hideaki ; Tomoda, Takeshi ; Yamamoto, Naoki ; Tsutsumi, Koichiro ; Kuwaki, Kenji ; Ohnishi, Hideki ; Ikeda, Fusao ; Nakamura, Shinichiro ; Shiraha, Hidenori ; Takaki, Akinobu ; Okada, Hiroyuki ; Amano, Maho ; Nishimura, Shin Ichiro ; Yamamoto, Kazuhide. / Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas. In: Pancreatology. 2015 ; Vol. 15, No. 4. pp. 432-438.
@article{67dfff0b06544ee09354290d52c36fb1,
title = "Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas",
abstract = "Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95{\%} confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95{\%} CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.",
keywords = "Biological markers, Fucosylation, Glycomics, Intraductal papillary mucinous neoplasm, Malignancy, Pancreas",
author = "Yutaka Akimoto and Kazuhiro Nouso and Hironari Katou and Koji Miyahara and Chihiro Dohi and Yuki Morimoto and Hideaki Kunugasa and Takeshi Tomoda and Naoki Yamamoto and Koichiro Tsutsumi and Kenji Kuwaki and Hideki Ohnishi and Fusao Ikeda and Shinichiro Nakamura and Hidenori Shiraha and Akinobu Takaki and Hiroyuki Okada and Maho Amano and Nishimura, {Shin Ichiro} and Kazuhide Yamamoto",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.pan.2015.05.470",
language = "English",
volume = "15",
pages = "432--438",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

AU - Akimoto, Yutaka

AU - Nouso, Kazuhiro

AU - Katou, Hironari

AU - Miyahara, Koji

AU - Dohi, Chihiro

AU - Morimoto, Yuki

AU - Kunugasa, Hideaki

AU - Tomoda, Takeshi

AU - Yamamoto, Naoki

AU - Tsutsumi, Koichiro

AU - Kuwaki, Kenji

AU - Ohnishi, Hideki

AU - Ikeda, Fusao

AU - Nakamura, Shinichiro

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Okada, Hiroyuki

AU - Amano, Maho

AU - Nishimura, Shin Ichiro

AU - Yamamoto, Kazuhide

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95% confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95% CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.

AB - Background/objectives Diagnosing the invasiveness of intraductal papillary mucinous neoplasms (IPMNs) is difficult, especially by blood test. Alterations in serum glycan profiles have been reported for several cancers, but changes in serum glycan profiles have not been investigated in patients with IPMNs. The objectives of this study were to determine the serum N-glycan profile and to investigate its clinical utility in patients with IPMNs. Methods We measured serum N-glycan profiles in 79 patients with IPMNs, including 13 invasive IPMNs, by performing comprehensive glycome analysis and assessed the relationship between N-glycan changes and clinical parameters. Results Seventy glycans were identified and their expression profiles were significantly different depending on the cyst size, the presence of an enhancing solid component, and the histological grade of the IPMN. Nine glycans were highly expressed in patients with invasive IPMNs. The glycan m/z 3195, which is a fucosylated tri-antennary glycan, had the highest diagnostic value for distinguishing invasive IPMNs from non-invasive IPMNs (area under the receiver operating characteristic curve = 0.803). Multivariate analyses revealed high levels of m/z 3195 [odds ratio (OR), 20.5; 95% confidence interval (CI) 2.60-486.4] and the presence of enhancing solid components (OR, 35.8; 95% CI, 5.39-409.6) were significant risk factors for invasive IPMNs. Conclusions We performed a comprehensive evaluation of the changes in serum N-glycan profiles in patients with IPMNs for the first time. We determined that increased expression of fucosylated complex-type glycans, especially m/z 3195, is a potential marker for invasive IPMNs.

KW - Biological markers

KW - Fucosylation

KW - Glycomics

KW - Intraductal papillary mucinous neoplasm

KW - Malignancy

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=84937519917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937519917&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2015.05.470

DO - 10.1016/j.pan.2015.05.470

M3 - Article

C2 - 26052067

AN - SCOPUS:84937519917

VL - 15

SP - 432

EP - 438

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 4

ER -